Cargando…

Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive carcinoma entities worldwide with early and rapid dissemination. Recently, we discussed the role of microRNAs as epigenetic regulators of Epithelial-to-Mesenchymal Transition (EMT) in PDAC. In this study, we investigated their val...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhayat, Sameer Abdallah, Traeger, Max Michael, Rehkaemper, Jan, Stroese, Anda Jana, Steinestel, Konrad, Wardelmann, Eva, Kabar, Iyad, Senninger, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162771/
https://www.ncbi.nlm.nih.gov/pubmed/30217058
http://dx.doi.org/10.3390/cancers10090328
_version_ 1783359216839294976
author Dhayat, Sameer Abdallah
Traeger, Max Michael
Rehkaemper, Jan
Stroese, Anda Jana
Steinestel, Konrad
Wardelmann, Eva
Kabar, Iyad
Senninger, Norbert
author_facet Dhayat, Sameer Abdallah
Traeger, Max Michael
Rehkaemper, Jan
Stroese, Anda Jana
Steinestel, Konrad
Wardelmann, Eva
Kabar, Iyad
Senninger, Norbert
author_sort Dhayat, Sameer Abdallah
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive carcinoma entities worldwide with early and rapid dissemination. Recently, we discussed the role of microRNAs as epigenetic regulators of Epithelial-to-Mesenchymal Transition (EMT) in PDAC. In this study, we investigated their value as diagnostic and prognostic markers in tissue and blood samples of 185 patients including PDAC, non-malignant pancreatic disorders, and age-matched healthy controls. Expression of the microRNA-200-family (microRNAs -141, -200a, -200b, -200c, -429) and microRNA-148a was significantly downregulated in tissue of PDAC Union internationale contre le cancer (UICC) Stage II. Correspondingly, stromal PDAC tissue showed strong expression of Fibronectin, Vimentin, and ZEB-1 (Zinc finger E-box-binding homeobox) versus low expression of E-cadherin. Transient transfection of microRNA-200b and microRNA-200c mimics resulted in the downregulation of their key target ZEB-1. Inversely, blood serum analyses of patients with PDAC UICC Stages II, III, and IV showed a significant over-expression of microRNA-200-family members, microRNA-148a, microRNA-10b, and microRNA-34a. Correspondingly, Enzyme-linked Immunosorbent Assay (ELISA) analyses revealed a significant over-expression of soluble E-cadherin in serum samples of PDAC patients versus healthy controls. The best diagnostic accuracy to distinguish between PDAC and non-PDAC in this patient collective could be achieved in tissue by microRNA-148a with an area under the receiver-operating-characteristic (ROC) curve (AUC) of 0.885 and in blood serum by a panel of microRNA-141, -200b, -200c, and CA.19-9 with an AUC of 0.890. Both diagnostic tools outreach the diagnostic performance of the currently most common diagnostic biomarker CA.19-9 (AUC of 0.834). Kaplan Meier survival analysis of this patient collective revealed an improved overall survival in PDAC patients with high expression of tissue-related microRNA-34a, -141, -200b, -200c, and -429. In conclusion, EMT-regulating microRNAs have great potential as liquid and solid biopsy markers in PDAC patients. Their prognostic and therapeutic benefits remain important tasks for future studies.
format Online
Article
Text
id pubmed-6162771
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61627712018-10-02 Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma Dhayat, Sameer Abdallah Traeger, Max Michael Rehkaemper, Jan Stroese, Anda Jana Steinestel, Konrad Wardelmann, Eva Kabar, Iyad Senninger, Norbert Cancers (Basel) Article Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive carcinoma entities worldwide with early and rapid dissemination. Recently, we discussed the role of microRNAs as epigenetic regulators of Epithelial-to-Mesenchymal Transition (EMT) in PDAC. In this study, we investigated their value as diagnostic and prognostic markers in tissue and blood samples of 185 patients including PDAC, non-malignant pancreatic disorders, and age-matched healthy controls. Expression of the microRNA-200-family (microRNAs -141, -200a, -200b, -200c, -429) and microRNA-148a was significantly downregulated in tissue of PDAC Union internationale contre le cancer (UICC) Stage II. Correspondingly, stromal PDAC tissue showed strong expression of Fibronectin, Vimentin, and ZEB-1 (Zinc finger E-box-binding homeobox) versus low expression of E-cadherin. Transient transfection of microRNA-200b and microRNA-200c mimics resulted in the downregulation of their key target ZEB-1. Inversely, blood serum analyses of patients with PDAC UICC Stages II, III, and IV showed a significant over-expression of microRNA-200-family members, microRNA-148a, microRNA-10b, and microRNA-34a. Correspondingly, Enzyme-linked Immunosorbent Assay (ELISA) analyses revealed a significant over-expression of soluble E-cadherin in serum samples of PDAC patients versus healthy controls. The best diagnostic accuracy to distinguish between PDAC and non-PDAC in this patient collective could be achieved in tissue by microRNA-148a with an area under the receiver-operating-characteristic (ROC) curve (AUC) of 0.885 and in blood serum by a panel of microRNA-141, -200b, -200c, and CA.19-9 with an AUC of 0.890. Both diagnostic tools outreach the diagnostic performance of the currently most common diagnostic biomarker CA.19-9 (AUC of 0.834). Kaplan Meier survival analysis of this patient collective revealed an improved overall survival in PDAC patients with high expression of tissue-related microRNA-34a, -141, -200b, -200c, and -429. In conclusion, EMT-regulating microRNAs have great potential as liquid and solid biopsy markers in PDAC patients. Their prognostic and therapeutic benefits remain important tasks for future studies. MDPI 2018-09-13 /pmc/articles/PMC6162771/ /pubmed/30217058 http://dx.doi.org/10.3390/cancers10090328 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dhayat, Sameer Abdallah
Traeger, Max Michael
Rehkaemper, Jan
Stroese, Anda Jana
Steinestel, Konrad
Wardelmann, Eva
Kabar, Iyad
Senninger, Norbert
Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title_full Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title_fullStr Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title_short Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
title_sort clinical impact of epithelial-to-mesenchymal transition regulating micrornas in pancreatic ductal adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162771/
https://www.ncbi.nlm.nih.gov/pubmed/30217058
http://dx.doi.org/10.3390/cancers10090328
work_keys_str_mv AT dhayatsameerabdallah clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT traegermaxmichael clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT rehkaemperjan clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT stroeseandajana clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT steinestelkonrad clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT wardelmanneva clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT kabariyad clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma
AT senningernorbert clinicalimpactofepithelialtomesenchymaltransitionregulatingmicrornasinpancreaticductaladenocarcinoma